NDAINTRAVENOUSSOLUTIONPriority Review
Approved
Sep 1991
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Priority Review
FOSCAVIR (foscarnet sodium) by Bayer is mechanism of action foscarnet exerts its antiviral activity by a selective inhibition at the pyrophosphate binding site on virus-specific dna polymerases at concentrations that do not affect cellular dna polymerases. First approved in 1991.
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FOSCAVIR (foscarnet sodium) is an intravenous antiviral solution approved in 1991 that selectively inhibits virus-specific DNA polymerases without requiring cellular kinase activation. It is indicated for treatment of cytomegalovirus (CMV) infections and herpes simplex virus (HSV) in immunocompromised patients. The drug works by blocking the pyrophosphate binding site on viral enzymes, making it effective against acyclovir-resistant strains.
LOE Approaching
Product is in late-stage lifecycle with minimal linked job openings; team size likely smaller and focused on maintenance rather than growth initiatives.
Mechanism of Action
Mechanism of Action Foscarnet exerts its antiviral activity by a selective inhibition at the pyrophosphate binding site on virus-specific DNA polymerases at concentrations that do not affect cellular DNA polymerases. Foscarnet does not require activation (phosphorylation) by thymidine kinase or…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on FOSCAVIR offers limited career growth given its LOE-approaching status and zero linked job openings; this is a maintenance product with stable but small teams. Career value lies in defending market position in specialized immunocompromised patient populations and ensuring compliance and supply continuity rather than driving innovation or market expansion.
Regulatory Affairs Specialist
Worked on FOSCAVIR at Bayer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.